GLIATECH ADCON-L ANTI-ADHESION GEL APPROVABLE FOR REDUCING PERIDURAL FIBROSIS AFTER LUMBAR SURGERY, FDA PANEL SAYS; DATA DO NOT SUPPORT PAIN RELIEF CLAIM
This article was originally published in The Gray Sheet
Gliatech's Adcon-L anti-adhesion gel should include in final labeling a statement explaining that no data exist to support long-term pain relief, FDA's Orthopedic and Rehabilitation Devices Advisory Panel recommended at a Dec. 12 meeting. The suggestion was one of several conditions for FDA approval of a premarket approval application for Adcon-L in reducing peridural fibrosis and adhesions following single-level (L4-L5 or L5-S1), posterior lumbar laminectomy or discectomy.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.